Non-alcoholic fatty liver disease: A brief review

被引:19
作者
van Hoek, B [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, NL-2300 RC Leiden, Netherlands
关键词
diabetes mellitus; hepatitis; insulin resistance; metformin; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; obesity; oxygen radicals; steatosis; ursodeoxycholic acid;
D O I
10.1080/00855920410011013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The term 'non-alcoliolic fatty liver disease' (NAFLD) includes cases with steatosis alone and those with non-alcoholic steatohepatitis (NASH). Usually there are no signs or symptoms, sometimes fatigue or pain, and apart from hepatomegaly the condition is revealed by abnormal liver biochemistry or by abdominal ultrasound. Most cases are associated with overweight or diabetes. Liver enzymes are usually elevated, especially GGT, ASAT and ALAT. Other conditions, including alcohol abuse and autoimmune hepatitis, have to be excluded. The diagnosis of steatosis can be made with ultrasound or CT scan. A liver biopsy is often needed to exclude other disease and to assess inflammation and fibrosis. Cirrhosis can develop. NAFLD is usually caused by two 'hits': the 'first hit' is peripheral insulin resistance, causing steatosis. The 'second hit' is caused by reactive oxygen species, inducing vicious cycles leading to inflammation. Weight loss, metformin or thiazolidinediones can improve NAFLD by increasing insulin sensitivity. Radical scavengers such as vitamin E. betaine and perhaps also urodeoxycholic acid may improve the hepatitis component. Further studies on treatment are needed.
引用
收藏
页码:56 / 59
页数:4
相关论文
共 58 条
[1]  
Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711
[2]  
American Gastroenterological Association, 2002, GASTROENTEROLOGY, V123, P1702, DOI 10.1053/gast.2002.36569
[3]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[4]   NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109
[5]   DIABETIC HEPATITIS PRECEDING THE ONSET OF GLUCOSE-INTOLERANCE [J].
BATMAN, PA ;
SCHEUER, PJ .
HISTOPATHOLOGY, 1985, 9 (02) :237-243
[6]   Hepatic Steatosis as a Potential Risk Factor for Major Hepatic Resection [J].
Behrns K.E. ;
Tsiotos G.G. ;
DeSouza N.F. ;
Krishna M.K. ;
Ludwig J. ;
Nagorney D.M. .
Journal of Gastrointestinal Surgery, 1998, 2 (3) :292-298
[7]  
BERKOWITZ D, 1964, JAMA-J AM MED ASSOC, V187, P103
[8]   Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions [J].
Brunt, EM ;
Janney, CG ;
Di Bisceglie, AM ;
Neuschwander-Tetri, BA ;
Bacon, BR .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (09) :2467-2474
[9]   Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease [J].
Caldwell, SH ;
Oelsner, DH ;
Iezzoni, JC ;
Hespenheide, EE ;
Battle, EH ;
Driscoll, CJ .
HEPATOLOGY, 1999, 29 (03) :664-669
[10]  
Caldwell SH, 2001, AM J GASTROENTEROL, V96, P519